ClouDr Group (HKSE:09955) ROCE %: -90.82% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:09955 ClouDr Group Ltd HKSE:09955
48 GF Score
Price HK$0.51
GF Value HK$0.81
Valuation Possible Value Trap
! 9 Warning Signs
View Full Analysis

What is ClouDr Group ROCE %?

ClouDr Group HKSE:09955 +3.03% 48 ROCE % is -90.82% as of Dec. 2025. GuruFocus rates HKSE:09955 with a GF Score™ of 48/100 and a GF Value™ of HK$0.81 (Possible Value Trap). The stock has 9 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. ClouDr Group's annualized ROCE % for the quarter that ended in Dec. 2025 was -90.82%.

ClouDr Group  (HKSE:09955) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

ClouDr Group ROCE % Related Terms

ClouDr Group ROCE % Historical Data

* Premium members only.

The historical data trend for ClouDr Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ClouDr Group ROCE % Chart

ClouDr Group Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial 0.00 0.00 -16.51 -28.04 -96.47

ClouDr Group Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.38 -11.89 -43.96 -108.67 -90.82
HKSE:09955
48GF Score
ClouDr Group Ltd HKSE:09955
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ClouDr Group ROCE % Calculation

ClouDr Group's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-1055.189/( ( (3036.675 - 1444.805) + (1860.363 - 1264.619) )/ 2 )
=-1055.189/( (1591.87+595.744)/ 2 )
=-1055.189/1093.807
=-96.47 %

ClouDr Group's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-707.626/( ( (2355.492 - 1392.966) + (1860.363 - 1264.619) )/ 2 )
=-707.626/( ( 962.526 + 595.744 )/ 2 )
=-707.626/779.135
=-90.82 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -90.82% mean?
ClouDr Group (HKSE:09955) has a ROCE % of -90.82% as of Dec. 2025.
Is ClouDr Group's ROCE % too high?
ClouDr Group's current ROCE % is -90.82%. Overall, ClouDr Group has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ClouDr Group's ROCE % compare to MCK and COR?
ClouDr Group's ROCE % of -90.82% can be compared against companies in the Medical Distribution industry. The industry median ROCE % is 8.92. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Distribution company?
The median ROCE % among Medical Distribution companies is 8.92, based on 120 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median ROCE % is 8.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ClouDr Group's current ROCE % is -90.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ClouDr Group stock overvalued right now?
Based on GuruFocus' analysis, ClouDr Group (HKSE:09955) is currently considered Possible Value Trap. The stock's GF Value™ is HK$0.81, compared to a current price of HK$0.51 — trading 37% below its estimated fair value. The current ROCE % is -90.82%. ClouDr Group's overall GF Score™ is 48/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For ClouDr Group (HKSE:09955), the current ROCE % is -90.82% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ClouDr Group (HKSE:09955) Overvalued in 2026?

Based on GuruFocus' analysis, ClouDr Group stock appears to be undervalued. The current stock price of HK$0.51 is trading 37% below its estimated GF Value™ of HK$0.81. GuruFocus considers ClouDr Group to be Possible Value Trap.

Key valuation signals for HKSE:09955:

  • ROCE %: -90.82%
  • GF Value™: HK$0.81 vs. price of HK$0.51 (37% below fair value)
  • GF Score™: 48/100 with 9 warning signs

No single metric tells the full story. See the HKSE:09955 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ClouDr Group Business Description

Address No. 998 Wenyi West Road (Haichuang Yuan), Wuchang Street, Rooms 501, 5th Floor, Building 12, Yuhang District, Zhejiang Province, Hangzhou, CHN
ClouDr Group Ltd provides supplies and SaaS to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultation and prescriptions to patients, all centered around chronic condition management. The company's in-hospital solution consists of sales of medical devices, consumables, and pharmaceuticals, hospital SaaS, and digital marketing services to pharmaceutical companies, and the out-of-hospital solution connects doctors and patients, and provides high-quality and trustworthy medical services through the AI vertical model ClouD GPT. The company generates revenues from sales of hospital and pharmacy supplies and individual chronic condition management products.
48GF Score

Get the complete analysis for HKSE:09955

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.51
Price
HK$0.81
GF Value